Lexeo reports positive interim Phase 1/2 data for LX2006 in FA cardiomyopathy; 25% LVMI reduction

Lexeo Therapeutics, Inc.

Participants with abnormal LVMI at baseline achieved 25% mean reduction by 12 months or sooner.
High-dose cohort (Cohort 3) showed 115% mean increase in cardiac frataxin expression at 3 months.
LX2006 well tolerated; no Grade 3+ SAEs, no complement activation, no discontinuations.
FDA alignment on co-primary endpoints (LVMI >10% improvement, any frataxin increase) for registrational study.
Registrational study expected to initiate by early 2026; natural history study enrollment starts Q2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.